Abstract
Surgical intervention for congenital heart disease (CHD) can be complicated by pulmonary hypertension (PH), which increases morbidity, mortality, and medical burden. Consequently, postoperative management of PH is an important clinical consideration to improve outcomes. Inhaled nitric oxide (iNO) is a widely accepted standard of care for PH and has been studied in the context of cardiac surgery for CHD. However, large randomized, double-blind, placebo-controlled, multicenter clinical trials in pediatric patients are limited. This review will provide an overview of the clinical studies in this setting and will discuss general treatment considerations to facilitate a better understanding of the clinical use of iNO for PH after pediatric cardiac surgery.
Similar content being viewed by others
References
Adatia I, Beghetti M (2009) Immediate postoperative care. Cardiol Young 19(Suppl 1):23–27
Atz AM, Wessel DL (1999) Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91:307–310
Bacha EA et al (2000) Management of pulmonary arteriovenous malformations after surgery for complex congenital heart disease. J Thorac Cardiovasc Surg 119:175–176
Beghetti M et al (1995) Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 73:65–68
Beghetti M et al (1998) Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury. Ann Thorac Surg 66:532–534
Behrends M, Beiderlinden M, Peters J (2005) Combination of sildenafil and bosentan for nitric oxide withdrawal. Eur J Anaesthesiol 22:155–157
Botha P et al (2007) Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 26:1199–1205
Brown KL et al (2003) Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med 31:28–33
Carmona MJ, Auler JO Jr (1998) Effects of inhaled nitric oxide on respiratory system mechanics, hemodynamics, and gas exchange after cardiac surgery. J Cardiothorac Vasc Anesth 12:157–161
Costard-Jackle A, Fowler MB (1992) Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19:48–54
Crosswhite P, Sun Z (2010) Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 28:201–212
Curran RD et al (1995) Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. Ann Thorac Surg 60:1765–1771
Daftari B, Alejos JC, Perens G (2010) Initial experience with sildenafil, bosentan, and nitric oxide for pediatric cardiomyopathy patients with elevated pulmonary vascular resistance before and after orthotopic heart transplantation. J Transplant 2010:1–6
Davidson D et al (1999) Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 104:231–236
Day RW et al (2000) Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease. Ann Thorac Surg 69:1907–1912
El Kebir D et al (2005) Effects of inhaled nitric oxide on inflammation and apoptosis after cardiopulmonary bypass. Chest 128:2910–2917
Elahi MM et al (2009) Inspired nitric oxide and modulation of oxidative stress during cardiac surgery. Curr Drug Saf 4:188–198
Fullerton DA et al (1996) Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. J Thorac Cardiovasc Surg 111:753–762
Gamillscheg A et al (1997) Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis. J Thorac Cardiovasc Surg 113:435–442
Gianetti J et al (2004) Supplemental nitric oxide and its effect on myocardial injury and function in patients undergoing cardiac surgery with extracorporeal circulation. J Thorac Cardiovasc Surg 127:44–50
Giglia TM, Humpl T (2010) Preoperative pulmonary hemodynamics and assessment of operability: Is there a pulmonary vascular resistance that precludes cardiac operation? Pediatr Crit Care Med 11:S57–S69
Gladwin MT, Crawford JH, Patel RP (2004) The biochemistry of nitric oxide, nitrite, and hemoglobin: Role in blood flow regulation. Free Radic Biol Med 36:707–717
Goldman AP et al (1996) Pharmacological control of pulmonary blood flow with inhaled nitric oxide after the fenestrated Fontan operation. Circulation 94:II44–II48
Gothberg S, Edberg KE (2000) Inhaled nitric oxide to newborns and infants after congenital heart surgery on cardiopulmonary bypass: a dose-response study. Scand Cardiovasc J 34:154–158
Hamon I et al (2010) Methaemoglobinaemia risk factors with inhaled nitric oxide therapy in newborn infants. Acta Paediatr 99:1467–1473
Hawkins A, Tulloh R (2009) Treatment of pediatric pulmonary hypertension. Vasc Health Risk Manag 5:509–524
Haydar A et al (1992) Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects. Lancet 340:1545
Hermon M et al (1999) Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study. Artif Organs 23:975–978
Hermon MM et al (2003) Methemoglobin formation in children with congenital heart disease treated with inhaled nitric oxide after cardiac surgery. Intensive Care Med 29:447–452
Heron M et al (2010) Annual summary of vital statistics: 2007. Pediatrics 125:4–15
Hofer A et al (2002) Successful management of severe life-threatening hypoxemia due to pulmonary arteriovenous malformation. Anesthesiology 97:1313–1315
Hoffman JI, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39:1890–1900
Hopkins RA et al (1991) Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg 5:628–634
Hoskote A et al (2010) Acute right ventricular failure after pediatric cardiac transplant: predictors and long-term outcome in current era of transplantation medicine. J Thorac Cardiovasc Surg 139:146–153
INOmax [package insert] (2010) INO Therapeutics, Clinton, NJ
Ivy DD et al (1998) Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 115:875–882
Journois D et al (1994) Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 107:1129–1135
Journois D et al (2005) Effects of inhaled nitric oxide administration on early postoperative mortality in patients operated for correction of atrioventricular canal defects. Chest 128:3537–3544
Khambadkone S et al (2003) Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 107:3204–3208
Klinger JR (2007) The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 28:143–167
Kumar VH et al (2010) Exposure to supplemental oxygen and its effects on oxidative stress and antioxidant enzyme activity in term newborn lambs. Pediatr Res 67:66–71
Lang JD Jr et al (2007) Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 117:2583–2591
Lee JE, Hillier SC, Knoderer CA (2008) Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 23:329–334
Magazine HI et al (2000) Rebound from nitric oxide inhibition triggers enhanced monocyte activation and chemotaxis. J Immunol 165:102–107
McLaughlin VV et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119:2250–2294
Meade MO et al (2003) A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 167:1483–1489
Miller OI et al (1994) Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 108:487–494
Miller OI et al (1995) Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 346:51–52
Miller OI et al (2000) Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 356:1464–1469
Morris K et al (2000) Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease. Crit Care Med 28:2974–2978
Mychaskiw G, Sachdev V, Heath BJ (2001) Sildenafil (viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 13:218–220
Namachivayam P et al (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042–1047
Pagowska-Klimek I et al. (2011) Predictors of long intensive care unit stay following cardiac surgery in children. Eur J Cardiothorac Surg 40: 179–184
Pearl JM et al (2002) Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension. Crit Care Med 30:89–93
Radomski MW, Moncada S (1993) Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 70:36–41
Reiter CD et al (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389
Rich GF et al (1993) Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 78:1028–1035
Rosenzweig EB, Widlitz AC, Barst RJ (2004) Pulmonary arterial hypertension in children. Pediatr Pulmonol 38:2–22
Russell IA et al (1998) The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg 87:46–51
Sato H et al (1997) Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg 113:399–409
Schulze-Neick I et al (2001) Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg 121:1033–1039
Shimpo H et al (1997) Inhaled low-dose nitric oxide for postoperative care in patients with congenital heart defects. Artif Organs 21:10–13
Suesaowalak M, Cleary JP, Chang AC (2010) Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. World J Pediatr 6:13–31
Tang JR et al (2007) Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. Am J Physiol Lung Cell Mol Physiol 293:L1271–L1280
Tulloh RM (2005) Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 6:174–180
Turanlahti MI, Laitinen PO, Pesonen EJ (2000) Preoperative and postoperative response to inhaled nitric oxide. Scand Cardiovasc J 34:46–52
Urcelay GE et al (2005) Nitric oxide in pulmonary arteriovenous malformations and Fontan procedure. Ann Thorac Surg 80:338–340
Vinten-Johansen J et al (1999) Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann N Y Acad Sci 874:354–370
Wessel DL et al (1993) Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 88:2128–2138
Yahagi N et al (1994) Inhaled nitric oxide for the postoperative management of Fontan-type operations. Ann Thorac Surg 57:1371–1373
Yoshimura N et al (2005) Inhaled nitric oxide therapy after Fontan-type operations. Surg Today 35:31–35
Zobel G et al (1998) Inhaled nitric oxide in infants and children after open heart surgery. J Cardiovasc Surg (Torino) 39:79–86
Acknowledgments
The authors acknowledge Peloton Advantage, LLC, for providing editorial support for this article. This editorial support was funded by INO Therapeutics, LLC, a subsidiary of Ikaria, Inc. Editorial support for this article was provided by Peloton Advantage, LLC, and funded by INO Therapeutics, LLC, a subsidiary of Ikaria, Inc.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
See Appendix Table 5.
Rights and permissions
About this article
Cite this article
Checchia, P.A., Bronicki, R.A. & Goldstein, B. Review of Inhaled Nitric Oxide in the Pediatric Cardiac Surgery Setting. Pediatr Cardiol 33, 493–505 (2012). https://doi.org/10.1007/s00246-012-0172-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-012-0172-4